Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04743908 · ClinicalTrials.gov registry record · NA
Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US
A NA study, sponsored by University of Chicago.
- Completed
- Registry status
- NA
- Development phase
- 1,328
- Enrollment target
NCT04743908 is a NA study that has completed, run by University of Chicago. The registered enrollment target is 1,328 participants.
The verdict
NCT04743908, a NA study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,328 participants
- Enrollment target
Study Summary
This C3 project, Community network-driven COVID-19 testing of vulnerable populations in the Central US, will implement and evaluate a COVID-19 testing and vaccination approach that combines an evidence-based Social Network Testing Strategy (SNS) with community developed COVID-19 public health messages (SNS+). C3 will engage two disenfranchised populations across rural and urban sites in states across the Central US (Texas (TX), Louisiana (LA), Arkansas (AR), Indiana (IN), Illinois (IL)). C3 leverages NIDA's Justice Community Opioid Innovation Network (JCOIN), the PIs' extensive community located COVID-19 testing programs, and a network of established community partnerships. The collaborative community-academic partnerships, research and engagement infrastructure, and team's leadership across JCOIN will ensure that C3 can rapidly recruit, enroll and test most disenfranchised community members, (n=2400) and through this process, accelerate any forthcoming COVID-19 public health prevention interventions. C3 focuses on two communities most impacted by COVID-19: 1) Criminal justice involved (CJI) - non-incarcerated people with previous history of arrest/jail/prison, probation/parole, drug-court attendance, witnessed or experienced a negative interaction with police or law enforcement; and 2) Low-income Latinx - community members at 250% or below Federal Poverty Level. Both of these diverse populations, and the overlap between them, have some of the highest rates of COVID-19 infection and death in the United States. Messaging that affirms individual agency and corrects misinformation, combined with accessible and acceptable testing, is required to accelerate COVID-19 prevention for these populations.Using a two-arm randomized controlled trial design, participants will be enrolled into the Social Network testing Strategy (SNS) arm (involves social networking referrals only) or the Social Network testing Strategy with COVID-19 prevention messages (SNS+) messaging arm. The l
Interventions
- OTHER Social Network Strategy + COVID-19 messaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,328 participants |
| Start Date | 2021-04-29 |
| Est. Completion | 2022-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04743908
The ClinicalTrials.gov registry entry for NCT04743908 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,328 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Social Network Strategy + COVID-19 messaging is the first listed.
NCT04743908 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04743908 about?
NCT04743908 is a clinical study titled "Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US". This C3 project, Community network-driven COVID-19 testing of vulnerable populations in the Central US, will implement and evaluate a COVID-19 testing and vaccination approach that combines an evidence-based Social Network Testing Strategy (SNS) with community developed COVID-19 public health messag...
What is the current status of trial NCT04743908?
This trial is currently completed. It is a NA study. The enrollment target is 1,328 participants. The study started on 2021-04-29. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT04743908?
The interventions under investigation include: Social Network Strategy + COVID-19 messaging (OTHER).
Who is sponsoring clinical trial NCT04743908?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.